Last reviewed · How we verify

NCT05270707

HyperArc Registry Study

Completed Last updated 24 September 2025
What this trial tests

trial testing Stereotactic radiosurgery in Brain Metastases in 968 participants. Completed in 31 March 2025.

Timeline
31 March 2022
Primary endpoint
31 March 2025
31 March 2025

Quick facts

Lead sponsorVarian, a Siemens Healthineers Company
StatusCompleted
Study typeOBSERVATIONAL
Enrollment968
Start date31 March 2022
Primary completion31 March 2025
Estimated completion31 March 2025
Sites7 locations across Belgium, Italy, United States, Australia

Drugs / interventions tested

Conditions studied

Sponsor

Varian, a Siemens Healthineers Company — full company profile →

Who can join

18 and older, any sex, with Brain Metastases or CNS Neoplasm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The HyperArc registry is designed to collect data from which the efficacy of the HyperArc procedure can be assessed and compared to alternative treatments.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Stereotactic radiosurgery

Trials testing the same drug.

Other recruiting trials for Brain Metastases

Currently open trials in the same condition.

Other Varian, a Siemens Healthineers Company trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05270707.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing